Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CymaBay Therapeutics, Inc.CBAY · Entity 92768 | Director | February 07, 2019 | February 08, 2019 |
| Damora Therapeutics, Inc.GLTO · Entity 4602 | Director | June 18, 2025 | June 20, 2025 |
| Enliven Therapeutics, Inc.IMRA · Entity 4024 | Director | June 02, 2022 | June 03, 2022 |
| ReShape Weightloss Inc.ETRM · Entity 137993 | Director | May 25, 2017 | May 31, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CymaBay Therapeutics, Inc.
Report date February 07, 2019 · Filed February 08, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2019-02-07 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2019-02-07 · Exercise / conversion · Acquired 2,335 · Balance 2,335 Row 2 · 2019-02-07 · Exercise / conversion · Acquired 9,340 · Balance 11,675 Row 3 · 2019-02-07 · Sale · Disposed 11,675 · Balance 0 F1: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.00 to $9.09, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.00 · Expires 2023-12-22 | Direct | 0 |
Reported balance
After 2019-02-07 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-02-07 · Exercise / conversion · Disposed 2,335 · Balance 0 F2: Fully vested. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.50 · Expires 2027-06-27 | Direct | 0 |
Reported balance
After 2019-02-07 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-02-07 · Exercise / conversion · Disposed 9,340 · Balance 0 F2: Fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.00 to $9.09, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2: Fully vested.
Damora Therapeutics, Inc.
Report date June 18, 2025 · Filed June 20, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.22 · Expires 2035-06-18 | Direct | 1,440 |
Reported balance
After 2025-06-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-06-18 · Grant · Acquired 1,440 · Balance 1,440 F1: Pursuant to the Issuer's Non-Employee Director Compensation Policy, this option was automatically granted on June 18, 2025, the date of the Issuer's 2025 Annual Meeting of Stockholders, with shares subject to the option vesting in equal monthly installments until the first anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Issuer's Non-Employee Director Compensation Policy, this option was automatically granted on June 18, 2025, the date of the Issuer's 2025 Annual Meeting of Stockholders, with shares subject to the option vesting in equal monthly installments until the first anniversary of the grant date.
Enliven Therapeutics, Inc.
Report date June 02, 2022 · Filed June 03, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.07 · Expires 2032-06-01 | Direct | 8,500 |
Reported balance
After 2022-06-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-06-02 · Grant · Acquired 8,500 · Balance 8,500 F2: The option will vest on the first anniversary of the date of grant or, if earlier, the date of Imara's next annual meeting of stockholders following the date of grant. |
| Common StockSEC Table I · non-derivative | IndirectBy entities affiliated with Bay City Capital LLC | 703,380 |
Reported balance
Holding disclosure · report date 2022-06-02 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 703,380 F1: Represents shares of common stock held by entities affiliated with Bay City Capital, LLC including Bay City Capital Fund V, L.P. and Bay City Capital Fund V Co-Investment Fund, L.P. Bay City Capital Management V LLC ("GP V") is the general partner of Bay City Capital Fund V, L.P. and Bay City Capital Fund V Co-Investment Fund, L.P. (collectively, "BCC V"). Bay City Capital, LLC ("BCC LLC") is the manager of GP V. The Reporting Person is an advisor of BCC LLC and a member of GP V and and shares voting and dispositive power with respect to shares held by BCC V. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of any pecuniary interest therein |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock held by entities affiliated with Bay City Capital, LLC including Bay City Capital Fund V, L.P. and Bay City Capital Fund V Co-Investment Fund, L.P. Bay City Capital Management V LLC ("GP V") is the general partner of Bay City Capital Fund V, L.P. and Bay City Capital Fund V Co-Investment Fund, L.P. (collectively, "BCC V"). Bay City Capital, LLC ("BCC LLC") is the manager of GP V. The Reporting Person is an advisor of BCC LLC and a member of GP V and and shares voting and dispositive power with respect to shares held by BCC V. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of any pecuniary interest therein
F2: The option will vest on the first anniversary of the date of grant or, if earlier, the date of Imara's next annual meeting of stockholders following the date of grant.
ReShape Weightloss Inc.
Report date May 25, 2017 · Filed May 31, 2017 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote. | 0 |
Reported balance
After 2017-05-25 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2017-05-25 · Sale · Disposed 4,571 · Balance 0 F2: This amendment is filed to correct the transaction code to note that shares sold were disposed of rather than acquired. F1: The price reported is the weighted average sale price for the transactions reported. The prices received ranged from $4.75 to $5.00. The Reporting Person will provide to the issuer, a security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range. F3: Represents shares held by Bay City Capital Fund IV, L.P. ("Fund IV"), including the shares held by Dr. Goldfischer; and indirect interests of Bay City Capital LLC ("BCC"), the manager of Bay City Capital Management IV LLC ("Management IV"), and Management IV, the general partner of Fund IV. Dr. Goldfischer is Managing Director of BCC. Dr. Goldfischer, BCC and Management IV each disclaims beneficial ownership in such shares, except to the extent of their pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote. | 0 |
Reported balance
After 2017-05-25 transaction · row 2
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 2 · 2017-05-25 · Sale · Disposed 97 · Balance 0 F2: This amendment is filed to correct the transaction code to note that shares sold were disposed of rather than acquired. F1: The price reported is the weighted average sale price for the transactions reported. The prices received ranged from $4.75 to $5.00. The Reporting Person will provide to the issuer, a security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range. F4: Represents shares held by Bay City Capital Fund IV Co-Investment Fund, L.P. ("Co-Investment IV"), including the shares held by Dr. Goldfischer; and indirect interests of BCC, the manager of Management IV, and Management IV, the general partner of Co-Investment IV. Dr. Goldfischer, BCC and Management IV each disclaims beneficial ownership in such shares, except to the extent of their pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported is the weighted average sale price for the transactions reported. The prices received ranged from $4.75 to $5.00. The Reporting Person will provide to the issuer, a security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range.
F2: This amendment is filed to correct the transaction code to note that shares sold were disposed of rather than acquired.
F3: Represents shares held by Bay City Capital Fund IV, L.P. ("Fund IV"), including the shares held by Dr. Goldfischer; and indirect interests of Bay City Capital LLC ("BCC"), the manager of Bay City Capital Management IV LLC ("Management IV"), and Management IV, the general partner of Fund IV. Dr. Goldfischer is Managing Director of BCC. Dr. Goldfischer, BCC and Management IV each disclaims beneficial ownership in such shares, except to the extent of their pecuniary interest therein.
F4: Represents shares held by Bay City Capital Fund IV Co-Investment Fund, L.P. ("Co-Investment IV"), including the shares held by Dr. Goldfischer; and indirect interests of BCC, the manager of Management IV, and Management IV, the general partner of Co-Investment IV. Dr. Goldfischer, BCC and Management IV each disclaims beneficial ownership in such shares, except to the extent of their pecuniary interest therein.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Epizyme, Inc.
Report date August 12, 2022 · Filed August 16, 2022
Section 16 reporting ended · disclosed 2022-08-16. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.0001SEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2022-08-12 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-08-12 · Disposition to issuer · Disposed 13,060 · Balance 8,994 F1: Reflects disposition of shares of common stock of the Issuer ("Shares") in connection with that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Ipsen Pharma SAS and Hibernia Merger Sub, Inc. ("Merger Sub"), dated as of June 27, 2022, including the completion of a tender offer to purchase all outstanding Shares of the Issuer, at a price per Share of (i) $1.45 per Share (the "Cash Consideration"), plus (ii) one (1) contractual contingent value right per Share ("CVR"), which represents the right to receive one or more contingent payments upon the achievement of certain milestones, if any (collectively, the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Merger Sub on August 12, 2022. As of the effective time of the Merger (the "Effective Time"), each Share held by the Reporting Person was converted into the Offer Price. Row 2 · 2022-08-12 · Disposition to issuer · Disposed 8,994 · Balance 0 F2: Reflects disposition of restricted stock units ("RSUs") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each unvested RSU held by the Reporting Person automatically vested in full and was canceled and converted into the right to receive (i) an amount of cash equal to the product of (A) the total number of Shares then underlying such RSU multiplied by (B) the Cash Consideration and (ii) one (1) CVR for each Share underlying such RSU, in each case, less applicable withholding. |
| Common Stock, par value $0.0001SEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2022-08-12 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2022-08-12 · Disposition to issuer · Disposed 3,380,951 · Balance 0 F1: Reflects disposition of shares of common stock of the Issuer ("Shares") in connection with that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Ipsen Pharma SAS and Hibernia Merger Sub, Inc. ("Merger Sub"), dated as of June 27, 2022, including the completion of a tender offer to purchase all outstanding Shares of the Issuer, at a price per Share of (i) $1.45 per Share (the "Cash Consideration"), plus (ii) one (1) contractual contingent value right per Share ("CVR"), which represents the right to receive one or more contingent payments upon the achievement of certain milestones, if any (collectively, the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Merger Sub on August 12, 2022. As of the effective time of the Merger (the "Effective Time"), each Share held by the Reporting Person was converted into the Offer Price. F3: Represents shares of common stock held by entities affiliated with Bay City Capital, LLC including Bay City Capital Fund V, L.P. and Bay City Capital Fund V Co-Investment Fund, L.P. Bay City Capital Management V LLC ("GP V") is the general partner of Bay City Capital Fund V, L.P. and Bay City Capital Fund V Co-Investment Fund, L.P. (collectively, "BCC V"). Bay City Capital, LLC ("BCC LLC") is the manager of GP V. The Reporting Person is an investment partner and managing director of BCC LLC and shares voting and dispositive power with respect to shares held by BCC V. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of any pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects disposition of shares of common stock of the Issuer ("Shares") in connection with that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Ipsen Pharma SAS and Hibernia Merger Sub, Inc. ("Merger Sub"), dated as of June 27, 2022, including the completion of a tender offer to purchase all outstanding Shares of the Issuer, at a price per Share of (i) $1.45 per Share (the "Cash Consideration"), plus (ii) one (1) contractual contingent value right per Share ("CVR"), which represents the right to receive one or more contingent payments upon the achievement of certain milestones, if any (collectively, the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Merger Sub on August 12, 2022. As of the effective time of the Merger (the "Effective Time"), each Share held by the Reporting Person was converted into the Offer Price.
F2: Reflects disposition of restricted stock units ("RSUs") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each unvested RSU held by the Reporting Person automatically vested in full and was canceled and converted into the right to receive (i) an amount of cash equal to the product of (A) the total number of Shares then underlying such RSU multiplied by (B) the Cash Consideration and (ii) one (1) CVR for each Share underlying such RSU, in each case, less applicable withholding.
F3: Represents shares of common stock held by entities affiliated with Bay City Capital, LLC including Bay City Capital Fund V, L.P. and Bay City Capital Fund V Co-Investment Fund, L.P. Bay City Capital Management V LLC ("GP V") is the general partner of Bay City Capital Fund V, L.P. and Bay City Capital Fund V Co-Investment Fund, L.P. (collectively, "BCC V"). Bay City Capital, LLC ("BCC LLC") is the manager of GP V. The Reporting Person is an investment partner and managing director of BCC LLC and shares voting and dispositive power with respect to shares held by BCC V. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of any pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 18, 2025 Filed Jun 20, 2025 07:00 UTC | Damora Therapeutics, Inc. GLTO · Entity 4602 | GrantStock Option (right to buy) · Derivative | 1,440 | $0.00 Strike: $3.22 | $0.00 |
DisclosureSEC source: 0000950170-25-088162 · ownership.xml · derivative · entry 1 GOLDFISCHER CARL · CIK 0001110780 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,440 Underlying: Common Stock · 1,440 shares Expires 2035-06-18 F1 · derivative.exercise_date: Pursuant to the Issuer's Non-Employee Director Compensation Policy, this option was automatically granted on June 18, 2025, the date of the Issuer's 2025 Annual Meeting of Stockholders, with shares subject to the option vesting in equal monthly installments until the first anniversary of the grant date. Read SEC document |
| June 20, 2024 Filed Jun 21, 2024 16:00 UTC | Damora Therapeutics, Inc. GLTO · Entity 4602 | GrantStock Option (right to buy) · Derivative | 36,000 | $0.00 Strike: $0.49 | $0.00 |
DisclosureSEC source: 0000950170-24-076187 · ownership.xml · derivative · entry 1 GOLDFISCHER CARL · CIK 0001110780 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,000 Underlying: Common Stock · 36,000 shares Expires 2034-06-19 F1 · derivative.exercise_date: Pursuant to the Issuer's Non-Employee Director Compensation Policy, this option was automatically granted on June 20, 2024, the date of the Issuer's 2024 Annual Meeting of Stockholders, with shares subject to the option vesting in equal monthly installments until the first anniversary of the grant date. Read SEC document |
| June 14, 2023 Filed Jun 15, 2023 16:00 UTC | Damora Therapeutics, Inc. GLTO · Entity 4602 | GrantStock Option (right to buy) · Derivative | 36,000 | $0.00 Strike: $2.12 | $0.00 |
DisclosureSEC source: 0001209191-23-037285 · doc4.xml · derivative · entry 1 GOLDFISCHER CARL · CIK 0001110780 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,000 Underlying: Common Stock · 36,000 shares Expires 2033-06-13 F1 · derivative.exercise_date: Pursuant to the Issuer's Non-Employee Director Compensation Policy, this option was automatically granted on June 14, 2023, the date of the Issuer's 2023 Annual Meeting of Stockholders, with shares subject to the option vesting in equal monthly installments until the first anniversary of the grant date. Read SEC document |
| August 12, 2022 Filed Aug 16, 2022 19:02 UTC | Epizyme, Inc. EPZM · Entity 12703 | Disposition to issuerCommon Stock, par value $0.0001 | 3,380,951 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-028874 · doc4.xml · nonDerivative · entry 3 GOLDFISCHER CARL · CIK 0001110780 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F1 · shares: Reflects disposition of shares of common stock of the Issuer ("Shares") in connection with that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Ipsen Pharma SAS and Hibernia Merger Sub, Inc. ("Merger Sub"), dated as of June 27, 2022, including the completion of a tender offer to purchase all outstanding Shares of the Issuer, at a price per Share of (i) $1.45 per Share (the "Cash Consideration"), plus (ii) one (1) contractual contingent value right per Share ("CVR"), which represents the right to receive one or more contingent payments upon the achievement of certain milestones, if any (collectively, the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Merger Sub on August 12, 2022. As of the effective time of the Merger (the "Effective Time"), each Share held by the Reporting Person was converted into the Offer Price. F1 · price: Reflects disposition of shares of common stock of the Issuer ("Shares") in connection with that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Ipsen Pharma SAS and Hibernia Merger Sub, Inc. ("Merger Sub"), dated as of June 27, 2022, including the completion of a tender offer to purchase all outstanding Shares of the Issuer, at a price per Share of (i) $1.45 per Share (the "Cash Consideration"), plus (ii) one (1) contractual contingent value right per Share ("CVR"), which represents the right to receive one or more contingent payments upon the achievement of certain milestones, if any (collectively, the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Merger Sub on August 12, 2022. As of the effective time of the Merger (the "Effective Time"), each Share held by the Reporting Person was converted into the Offer Price. F3 · ownership.nature: Represents shares of common stock held by entities affiliated with Bay City Capital, LLC including Bay City Capital Fund V, L.P. and Bay City Capital Fund V Co-Investment Fund, L.P. Bay City Capital Management V LLC ("GP V") is the general partner of Bay City Capital Fund V, L.P. and Bay City Capital Fund V Co-Investment Fund, L.P. (collectively, "BCC V"). Bay City Capital, LLC ("BCC LLC") is the manager of GP V. The Reporting Person is an investment partner and managing director of BCC LLC and shares voting and dispositive power with respect to shares held by BCC V. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of any pecuniary interest therein. Read SEC document |
| August 12, 2022 Filed Aug 16, 2022 19:02 UTC | Epizyme, Inc. EPZM · Entity 12703 | Disposition to issuerCommon Stock, par value $0.0001 | 8,994 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-028874 · doc4.xml · nonDerivative · entry 2 GOLDFISCHER CARL · CIK 0001110780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · shares: Reflects disposition of restricted stock units ("RSUs") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each unvested RSU held by the Reporting Person automatically vested in full and was canceled and converted into the right to receive (i) an amount of cash equal to the product of (A) the total number of Shares then underlying such RSU multiplied by (B) the Cash Consideration and (ii) one (1) CVR for each Share underlying such RSU, in each case, less applicable withholding. F2 · price: Reflects disposition of restricted stock units ("RSUs") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each unvested RSU held by the Reporting Person automatically vested in full and was canceled and converted into the right to receive (i) an amount of cash equal to the product of (A) the total number of Shares then underlying such RSU multiplied by (B) the Cash Consideration and (ii) one (1) CVR for each Share underlying such RSU, in each case, less applicable withholding. Read SEC document |
| August 12, 2022 Filed Aug 16, 2022 19:02 UTC | Epizyme, Inc. EPZM · Entity 12703 | Disposition to issuerCommon Stock, par value $0.0001 | 13,060 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-028874 · doc4.xml · nonDerivative · entry 1 GOLDFISCHER CARL · CIK 0001110780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,994 F1 · shares: Reflects disposition of shares of common stock of the Issuer ("Shares") in connection with that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Ipsen Pharma SAS and Hibernia Merger Sub, Inc. ("Merger Sub"), dated as of June 27, 2022, including the completion of a tender offer to purchase all outstanding Shares of the Issuer, at a price per Share of (i) $1.45 per Share (the "Cash Consideration"), plus (ii) one (1) contractual contingent value right per Share ("CVR"), which represents the right to receive one or more contingent payments upon the achievement of certain milestones, if any (collectively, the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Merger Sub on August 12, 2022. As of the effective time of the Merger (the "Effective Time"), each Share held by the Reporting Person was converted into the Offer Price. F1 · price: Reflects disposition of shares of common stock of the Issuer ("Shares") in connection with that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Ipsen Pharma SAS and Hibernia Merger Sub, Inc. ("Merger Sub"), dated as of June 27, 2022, including the completion of a tender offer to purchase all outstanding Shares of the Issuer, at a price per Share of (i) $1.45 per Share (the "Cash Consideration"), plus (ii) one (1) contractual contingent value right per Share ("CVR"), which represents the right to receive one or more contingent payments upon the achievement of certain milestones, if any (collectively, the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Merger Sub on August 12, 2022. As of the effective time of the Merger (the "Effective Time"), each Share held by the Reporting Person was converted into the Offer Price. Read SEC document |
| June 14, 2022 Filed Jun 15, 2022 16:00 UTC | Damora Therapeutics, Inc. GLTO · Entity 4602 | GrantStock Option (right to buy) · Derivative | 36,000 | $0.00 Strike: $1.98 | $0.00 |
DisclosureSEC source: 0001209191-22-036932 · doc4.xml · derivative · entry 1 GOLDFISCHER CARL · CIK 0001110780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,000 Underlying: Common Stock · 36,000 shares Expires 2032-06-13 F1 · derivative.exercise_date: Pursuant to the Issuer's Non-Employee Director Compensation Policy, this option was automatically granted on June 14, 2022, the date of the Issuer's 2022 Annual Meeting of Stockholder, with shares subject to the option vesting in equal monthly installments until the first anniversary of the grant date. Read SEC document |
| June 02, 2022 Filed Jun 3, 2022 20:21 UTC | Enliven Therapeutics, Inc. IMRA · Entity 4024 | GrantStock Options (Right to Buy) · Derivative | 8,500 | $0.00 Strike: $1.07 | $0.00 |
DisclosureSEC source: 0001209191-22-034390 · doc4.xml · derivative · entry 2 GOLDFISCHER CARL · CIK 0001110780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,500 Underlying: Common Stock · 8,500 shares Expires 2032-06-01 F2 · derivative.exercise_date: The option will vest on the first anniversary of the date of grant or, if earlier, the date of Imara's next annual meeting of stockholders following the date of grant. Read SEC document |
| May 17, 2022 Filed May 19, 2022 16:23 UTC | Epizyme, Inc. EPZM · Entity 12703 | GrantStock Option (Right to Buy) · Derivative | 41,006 | $0.00 Strike: $0.56 | $0.00 |
DisclosureSEC source: 0000899243-22-018818 · doc4.xml · derivative · entry 3 GOLDFISCHER CARL · CIK 0001110780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,006 Underlying: Common Stock · 41,006 shares Expires 2032-05-16 F3 · derivative.exercise_date: This option was granted on May 17, 2022 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service as a director. In the event of a change in control of the Issuer, the option will become exercisable in full. Read SEC document |
| May 17, 2022 Filed May 19, 2022 16:23 UTC | Epizyme, Inc. EPZM · Entity 12703 | GrantCommon Stock, par value $0.0001 | 8,994 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-018818 · doc4.xml · nonDerivative · entry 1 GOLDFISCHER CARL · CIK 0001110780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,054 F1 · shares: Consists of shares of Common Stock issuable under 8,994 restricted stock units ("RSUs") granted on May 17, 2022, which RSUs are scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service as a director. Each RSU represents the right to receive one share of Common Stock upon vesting. In the event of a change in control of the Issuer, the RSUs will vest in full. Read SEC document |
| November 17, 2021 Filed Nov 19, 2021 17:00 UTC | Damora Therapeutics, Inc. GLTO · Entity 4602 | GrantStock Option (right to buy) · Derivative | 18,000 | $0.00 Strike: $3.23 | $0.00 |
DisclosureSEC source: 0001209191-21-065841 · doc4.xml · derivative · entry 1 GOLDFISCHER CARL · CIK 0001110780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2031-11-16 F1 · security: This stock option was granted to the Reporting Person for serving as the Chair of the Board. F2 · derivative.exercise_date: Shares subject to the option vest in equal monthly installments beginning July 1, 2021, when the Reporting Person became the Chair of the Board of the Issuer, until July 1, 2022. Read SEC document |
| June 29, 2021 Filed Jun 30, 2021 18:48 UTC | Enliven Therapeutics, Inc. IMRA · Entity 4024 | GrantStock Options (Right to Buy) · Derivative | 7,728 | $0.00 Strike: $8.12 | $0.00 |
DisclosureSEC source: 0001209191-21-044089 · doc4.xml · derivative · entry 2 GOLDFISCHER CARL · CIK 0001110780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,728 Underlying: Common Stock · 7,728 shares Expires 2031-06-28 F2 · derivative.exercise_date: The option will vest on the first anniversary of the date of grant or, if earlier, the date of Imara's next annual meeting of stockholders following the date of grant. Read SEC document |
| June 11, 2021 Filed Jun 15, 2021 16:35 UTC | Epizyme, Inc. EPZM · Entity 12703 | GrantStock Option (Right to Buy) · Derivative | 40,559 | $0.00 Strike: $8.53 | $0.00 |
DisclosureSEC source: 0000899243-21-023866 · doc4.xml · derivative · entry 3 GOLDFISCHER CARL · CIK 0001110780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,559 Underlying: Common Stock · 40,559 shares Expires 2031-06-10 F3 · derivative.exercise_date: This option was granted on June 11, 2021 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service as a director. In the event of a change in control of the Issuer, the option will become exercisable in full. Read SEC document |
| June 11, 2021 Filed Jun 15, 2021 16:35 UTC | Epizyme, Inc. EPZM · Entity 12703 | GrantCommon Stock, par value $0.0001 | 8,060 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-023866 · doc4.xml · nonDerivative · entry 1 GOLDFISCHER CARL · CIK 0001110780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,060 F1 · shares: Consists of shares of Common Stock issuable under 8,060 restricted stock units ("RSUs") granted on June 11, 2021, which RSUs are scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service as a director. Each RSU represents the right to receive one share of Common Stock upon vesting. In the event of a change in control of the Issuer, the RSUs will vest in full. Read SEC document |
| May 26, 2021 Filed May 28, 2021 16:00 UTC | Damora Therapeutics, Inc. GLTO · Entity 4602 | GrantStock Option (right to buy) · Derivative | 18,000 | $0.00 Strike: $4.93 | $0.00 |
DisclosureSEC source: 0001209191-21-036507 · doc4.xml · derivative · entry 1 GOLDFISCHER CARL · CIK 0001110780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2031-05-25 F1 · derivative.exercise_date: Pursuant to the Issuer's Non-Employee Director Compensation Policy, this option was automatically granted on May 26, 2021, the date of the Issuer's 2021 Annual Meeting of Stockholder, with shares subject to the option vesting in equal monthly installments until the first anniversary of the grant date. Read SEC document |
| November 11, 2020 Filed Nov 13, 2020 07:05 UTC | Epizyme, Inc. EPZM · Entity 12703 | PurchaseCommon Stock, par value $0.0001 | 5,000 | $12.07 | $60,350.00 |
DisclosureSEC source: 0000899243-20-030917 · doc4.xml · nonDerivative · entry 1 GOLDFISCHER CARL · CIK 0001110780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.98 per share to $12.10 per share, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 20:00 UTC | Damora Therapeutics, Inc. GLTO · Entity 4602 | ConversionSeries D Preferred Stock · Derivative | 3,688 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-030416 · doc4.xml · derivative · entry 7 GOLDFISCHER CARL · CIK 0001110780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,587 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: The Series C-3 Preferred Stock and Series D Preferred Stock (collectively, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date. F4 · derivative.exercise_date: The Series C-3 Preferred Stock and Series D Preferred Stock (collectively, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date. F4 · derivative.expiration_date: The Series C-3 Preferred Stock and Series D Preferred Stock (collectively, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 20:00 UTC | Damora Therapeutics, Inc. GLTO · Entity 4602 | ConversionSeries C-3 Preferred Stock · Derivative | 7,475 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-030416 · doc4.xml · derivative · entry 6 GOLDFISCHER CARL · CIK 0001110780 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 19,432 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: The Series C-3 Preferred Stock and Series D Preferred Stock (collectively, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date. F4 · derivative.exercise_date: The Series C-3 Preferred Stock and Series D Preferred Stock (collectively, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date. F4 · derivative.expiration_date: The Series C-3 Preferred Stock and Series D Preferred Stock (collectively, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date. F2 · ownership.nature: These shares are held by Bay City Capital Fund V Co-Investment Fund, L.P. ("Co-Investment V"). F3 · ownership.nature: The Reporting Person is an Investment Partner and Managing Director of Bay City Capital LLC, the manager of Bay City Capital Management V LLC ("Management V"). Management V is the general partner of Fund V and Co-Investment V. The Reporting Person may be deemed to share voting, investment and dispositive power with respect to the shares held by Fund V and Co-Investment V. Dr. Goldfischer disclaims beneficial ownership of such securities, except to the extent of his indirect pecuniary interest therein. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 20:00 UTC | Damora Therapeutics, Inc. GLTO · Entity 4602 | ConversionSeries C-3 Preferred Stock · Derivative | 392,367 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-030416 · doc4.xml · derivative · entry 5 GOLDFISCHER CARL · CIK 0001110780 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 1,020,036 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: The Series C-3 Preferred Stock and Series D Preferred Stock (collectively, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date. F4 · derivative.exercise_date: The Series C-3 Preferred Stock and Series D Preferred Stock (collectively, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date. F4 · derivative.expiration_date: The Series C-3 Preferred Stock and Series D Preferred Stock (collectively, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date. F1 · ownership.nature: These shares are held by Bay City Capital Fund V, L.P. ("Fund V"). F3 · ownership.nature: The Reporting Person is an Investment Partner and Managing Director of Bay City Capital LLC, the manager of Bay City Capital Management V LLC ("Management V"). Management V is the general partner of Fund V and Co-Investment V. The Reporting Person may be deemed to share voting, investment and dispositive power with respect to the shares held by Fund V and Co-Investment V. Dr. Goldfischer disclaims beneficial ownership of such securities, except to the extent of his indirect pecuniary interest therein. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 20:00 UTC | Damora Therapeutics, Inc. GLTO · Entity 4602 | ConversionCommon Stock | 19,432 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-030416 · doc4.xml · nonDerivative · entry 3 GOLDFISCHER CARL · CIK 0001110780 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 19,432 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: The Series C-3 Preferred Stock and Series D Preferred Stock (collectively, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date. F2 · ownership.nature: These shares are held by Bay City Capital Fund V Co-Investment Fund, L.P. ("Co-Investment V"). F3 · ownership.nature: The Reporting Person is an Investment Partner and Managing Director of Bay City Capital LLC, the manager of Bay City Capital Management V LLC ("Management V"). Management V is the general partner of Fund V and Co-Investment V. The Reporting Person may be deemed to share voting, investment and dispositive power with respect to the shares held by Fund V and Co-Investment V. Dr. Goldfischer disclaims beneficial ownership of such securities, except to the extent of his indirect pecuniary interest therein. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 20:00 UTC | Damora Therapeutics, Inc. GLTO · Entity 4602 | ConversionCommon Stock | 1,020,036 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-030416 · doc4.xml · nonDerivative · entry 2 GOLDFISCHER CARL · CIK 0001110780 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,020,036 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: The Series C-3 Preferred Stock and Series D Preferred Stock (collectively, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date. F1 · ownership.nature: These shares are held by Bay City Capital Fund V, L.P. ("Fund V"). F3 · ownership.nature: The Reporting Person is an Investment Partner and Managing Director of Bay City Capital LLC, the manager of Bay City Capital Management V LLC ("Management V"). Management V is the general partner of Fund V and Co-Investment V. The Reporting Person may be deemed to share voting, investment and dispositive power with respect to the shares held by Fund V and Co-Investment V. Dr. Goldfischer disclaims beneficial ownership of such securities, except to the extent of his indirect pecuniary interest therein. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 20:00 UTC | Damora Therapeutics, Inc. GLTO · Entity 4602 | ConversionCommon Stock | 9,587 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-030416 · doc4.xml · nonDerivative · entry 1 GOLDFISCHER CARL · CIK 0001110780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,587 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: The Series C-3 Preferred Stock and Series D Preferred Stock (collectively, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date. Read SEC document |
| September 25, 2020 Filed Nov 4, 2020 20:00 UTC | Damora Therapeutics, Inc. GLTO · Entity 4602 | GrantSeries D Preferred Stock · Derivative | 3,688 | $27.11 | $99,981.68 |
DisclosureSEC source: 0000899243-20-030416 · doc4.xml · derivative · entry 4 GOLDFISCHER CARL · CIK 0001110780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,688 Underlying: Common Stock · 9,587 shares Expires not disclosed F4 · derivative.exercise_price: The Series C-3 Preferred Stock and Series D Preferred Stock (collectively, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date. F5 · kind: This transaction occurred prior to the Issuer's initial public offering and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3. F4 · derivative.exercise_date: The Series C-3 Preferred Stock and Series D Preferred Stock (collectively, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date. F4 · derivative.expiration_date: The Series C-3 Preferred Stock and Series D Preferred Stock (collectively, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date. Read SEC document |
| May 29, 2020 Filed Jun 2, 2020 16:16 UTC | Epizyme, Inc. EPZM · Entity 12703 | GrantStock Option (Right to Buy) · Derivative | 14,013 | $0.00 Strike: $17.55 | $0.00 |
DisclosureSEC source: 0000899243-20-014898 · doc4.xml · derivative · entry 1 GOLDFISCHER CARL · CIK 0001110780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,013 Underlying: Common Stock · 14,013 shares Expires 2030-05-28 F1 · derivative.exercise_date: This option will vest in full on May 29, 2021, subject to Reporting Person's continued service as a director. In the event of a change in control of the Issuer, the option will become exercisable in full. Read SEC document |
| March 16, 2020 Filed Mar 16, 2020 17:12 UTC | Enliven Therapeutics, Inc. IMRA · Entity 4024 | GrantStock Option (right to buy) · Derivative | 15,457 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0000899243-20-008488 · doc4.xml · derivative · entry 9 GOLDFISCHER CARL · CIK 0001110780 · Director · 10% owner BAY CITY CAPITAL LLC · CIK 0001288452 · 10% owner Bay City Capital Management V LLC · CIK 0001461543 · 10% owner Bay City Capital Fund V, L.P. · CIK 0001401826 · 10% owner Bay City Capital Fund V Co-Investment Fund, L.P. · CIK 0001409813 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Bay City Capital LLC Disclosed balance after: 15,457 Underlying: Common Stock · 15,457 shares Expires 2030-03-15 F7 · derivative.exercise_date: The option vests in three equal installments on March 16, 2021, 2022 and 2023. F8 · ownership.nature: The securities are held directly by Bay City Capital LLC ("BCC LLC") and represent stock options granted to Dr. Goldfischer and transferred to BCC LLC pursuant to an agreement between Dr. Goldfischer and BCC LLC. Dr. Goldfischer disclaims beneficial ownership over the securities owned by BCC LLC except to the extent of his pecuniary interest, if any, in the securities by virtue of his role as managing director of BCC LLC. This report shall not be deemed an admission that the Dr. Goldfischer is the beneficial owner of such shares. Read SEC document |
| March 16, 2020 Filed Mar 16, 2020 17:12 UTC | Enliven Therapeutics, Inc. IMRA · Entity 4024 | ConversionSeries B Preferred Stock · Derivative | 16,103 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-008488 · doc4.xml · derivative · entry 8 GOLDFISCHER CARL · CIK 0001110780 · Director · 10% owner BAY CITY CAPITAL LLC · CIK 0001288452 · 10% owner Bay City Capital Management V LLC · CIK 0001461543 · 10% owner Bay City Capital Fund V, L.P. · CIK 0001401826 · 10% owner Bay City Capital Fund V Co-Investment Fund, L.P. · CIK 0001409813 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By entities affiliated with Bay City Capital LLC Disclosed balance after: 0 Underlying: Common Stock · 2,555 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: On March 16, 2020, the Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F6 · price: On March 16, 2020, the Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F6 · derivative.exercise_date: On March 16, 2020, the Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F6 · derivative.expiration_date: On March 16, 2020, the Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F1 · ownership.nature: Bay City Capital LLC, a Delaware limited liability company ("BCC"), Bay City Capital Management V LLC, a Delaware limited liability company ("Management V"), Bay City Capital Fund V, L.P., a Delaware limited partnership ("Fund V"), and Bay City Capital Fund V Co-Investment Fund, L.P., a Delaware limited partnership ("Co-Investment V") are deemed to be a "group" for the purposes of Section 13(d) under the Securities Exchange Act of 1934. Management V is the general partner of Fund V and Co-Investment V and has sole voting and dispositive power with respect to the securities held by Fund V and Co-Investment V. BCC, the manager of Management V, is also an advisor to Fund V and Co-Investment V and has sole voting and dispositive power with respect to the securities held by Fund V and Co-Investment V. Carl Goldfischer, a Managing Director of BCC, is a member of the Issuer's Board of Directors. F3 · ownership.nature: Represent securities held by Co-Investment V, including indirect interests of BCC and Management V. BCC and Management V each disclaims beneficial ownership with respect to these securities, except to the extent of their pecuniary interest therein. Read SEC document |
| March 16, 2020 Filed Mar 16, 2020 17:12 UTC | Enliven Therapeutics, Inc. IMRA · Entity 4024 | ConversionSeries B Preferred Stock · Derivative | 845,008 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-008488 · doc4.xml · derivative · entry 7 GOLDFISCHER CARL · CIK 0001110780 · Director · 10% owner BAY CITY CAPITAL LLC · CIK 0001288452 · 10% owner Bay City Capital Management V LLC · CIK 0001461543 · 10% owner Bay City Capital Fund V, L.P. · CIK 0001401826 · 10% owner Bay City Capital Fund V Co-Investment Fund, L.P. · CIK 0001409813 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By entities affiliated with Bay City Capital LLC Disclosed balance after: 0 Underlying: Common Stock · 134,148 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: On March 16, 2020, the Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F6 · price: On March 16, 2020, the Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F6 · derivative.exercise_date: On March 16, 2020, the Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F6 · derivative.expiration_date: On March 16, 2020, the Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F1 · ownership.nature: Bay City Capital LLC, a Delaware limited liability company ("BCC"), Bay City Capital Management V LLC, a Delaware limited liability company ("Management V"), Bay City Capital Fund V, L.P., a Delaware limited partnership ("Fund V"), and Bay City Capital Fund V Co-Investment Fund, L.P., a Delaware limited partnership ("Co-Investment V") are deemed to be a "group" for the purposes of Section 13(d) under the Securities Exchange Act of 1934. Management V is the general partner of Fund V and Co-Investment V and has sole voting and dispositive power with respect to the securities held by Fund V and Co-Investment V. BCC, the manager of Management V, is also an advisor to Fund V and Co-Investment V and has sole voting and dispositive power with respect to the securities held by Fund V and Co-Investment V. Carl Goldfischer, a Managing Director of BCC, is a member of the Issuer's Board of Directors. F2 · ownership.nature: Represent securities held by Fund V, including indirect interests of BCC and Management V. BCC and Management V each disclaims beneficial ownership with respect to these securities, except to the extent of their pecuniary interest therein. Read SEC document |
| March 16, 2020 Filed Mar 16, 2020 17:12 UTC | Enliven Therapeutics, Inc. IMRA · Entity 4024 | ConversionSeries A Preferred Stock · Derivative | 61,378 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-008488 · doc4.xml · derivative · entry 6 GOLDFISCHER CARL · CIK 0001110780 · Director · 10% owner BAY CITY CAPITAL LLC · CIK 0001288452 · 10% owner Bay City Capital Management V LLC · CIK 0001461543 · 10% owner Bay City Capital Fund V, L.P. · CIK 0001401826 · 10% owner Bay City Capital Fund V Co-Investment Fund, L.P. · CIK 0001409813 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By entities affiliated with Bay City Capital LLC Disclosed balance after: 0 Underlying: Common Stock · 9,741 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: On March 16, 2020, Series A Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F5 · price: On March 16, 2020, Series A Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F5 · derivative.exercise_date: On March 16, 2020, Series A Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F5 · derivative.expiration_date: On March 16, 2020, Series A Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F1 · ownership.nature: Bay City Capital LLC, a Delaware limited liability company ("BCC"), Bay City Capital Management V LLC, a Delaware limited liability company ("Management V"), Bay City Capital Fund V, L.P., a Delaware limited partnership ("Fund V"), and Bay City Capital Fund V Co-Investment Fund, L.P., a Delaware limited partnership ("Co-Investment V") are deemed to be a "group" for the purposes of Section 13(d) under the Securities Exchange Act of 1934. Management V is the general partner of Fund V and Co-Investment V and has sole voting and dispositive power with respect to the securities held by Fund V and Co-Investment V. BCC, the manager of Management V, is also an advisor to Fund V and Co-Investment V and has sole voting and dispositive power with respect to the securities held by Fund V and Co-Investment V. Carl Goldfischer, a Managing Director of BCC, is a member of the Issuer's Board of Directors. F3 · ownership.nature: Represent securities held by Co-Investment V, including indirect interests of BCC and Management V. BCC and Management V each disclaims beneficial ownership with respect to these securities, except to the extent of their pecuniary interest therein. Read SEC document |
| March 16, 2020 Filed Mar 16, 2020 17:12 UTC | Enliven Therapeutics, Inc. IMRA · Entity 4024 | ConversionSeries A Preferred Stock · Derivative | 3,220,915 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-008488 · doc4.xml · derivative · entry 5 GOLDFISCHER CARL · CIK 0001110780 · Director · 10% owner BAY CITY CAPITAL LLC · CIK 0001288452 · 10% owner Bay City Capital Management V LLC · CIK 0001461543 · 10% owner Bay City Capital Fund V, L.P. · CIK 0001401826 · 10% owner Bay City Capital Fund V Co-Investment Fund, L.P. · CIK 0001409813 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By entities affiliated with Bay City Capital LLC Disclosed balance after: 0 Underlying: Common Stock · 511,335 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: On March 16, 2020, Series A Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F5 · price: On March 16, 2020, Series A Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F5 · derivative.exercise_date: On March 16, 2020, Series A Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F5 · derivative.expiration_date: On March 16, 2020, Series A Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F1 · ownership.nature: Bay City Capital LLC, a Delaware limited liability company ("BCC"), Bay City Capital Management V LLC, a Delaware limited liability company ("Management V"), Bay City Capital Fund V, L.P., a Delaware limited partnership ("Fund V"), and Bay City Capital Fund V Co-Investment Fund, L.P., a Delaware limited partnership ("Co-Investment V") are deemed to be a "group" for the purposes of Section 13(d) under the Securities Exchange Act of 1934. Management V is the general partner of Fund V and Co-Investment V and has sole voting and dispositive power with respect to the securities held by Fund V and Co-Investment V. BCC, the manager of Management V, is also an advisor to Fund V and Co-Investment V and has sole voting and dispositive power with respect to the securities held by Fund V and Co-Investment V. Carl Goldfischer, a Managing Director of BCC, is a member of the Issuer's Board of Directors. F2 · ownership.nature: Represent securities held by Fund V, including indirect interests of BCC and Management V. BCC and Management V each disclaims beneficial ownership with respect to these securities, except to the extent of their pecuniary interest therein. Read SEC document |
| March 16, 2020 Filed Mar 16, 2020 17:12 UTC | Enliven Therapeutics, Inc. IMRA · Entity 4024 | ConversionSeries Seed Preferred Stock · Derivative | 5,372 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-008488 · doc4.xml · derivative · entry 4 GOLDFISCHER CARL · CIK 0001110780 · Director · 10% owner BAY CITY CAPITAL LLC · CIK 0001288452 · 10% owner Bay City Capital Management V LLC · CIK 0001461543 · 10% owner Bay City Capital Fund V, L.P. · CIK 0001401826 · 10% owner Bay City Capital Fund V Co-Investment Fund, L.P. · CIK 0001409813 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By entities affiliated with Bay City Capital LLC Disclosed balance after: 0 Underlying: Common Stock · 852 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: On March 16, 2020, the Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F4 · price: On March 16, 2020, the Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F4 · derivative.exercise_date: On March 16, 2020, the Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F4 · derivative.expiration_date: On March 16, 2020, the Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F1 · ownership.nature: Bay City Capital LLC, a Delaware limited liability company ("BCC"), Bay City Capital Management V LLC, a Delaware limited liability company ("Management V"), Bay City Capital Fund V, L.P., a Delaware limited partnership ("Fund V"), and Bay City Capital Fund V Co-Investment Fund, L.P., a Delaware limited partnership ("Co-Investment V") are deemed to be a "group" for the purposes of Section 13(d) under the Securities Exchange Act of 1934. Management V is the general partner of Fund V and Co-Investment V and has sole voting and dispositive power with respect to the securities held by Fund V and Co-Investment V. BCC, the manager of Management V, is also an advisor to Fund V and Co-Investment V and has sole voting and dispositive power with respect to the securities held by Fund V and Co-Investment V. Carl Goldfischer, a Managing Director of BCC, is a member of the Issuer's Board of Directors. F3 · ownership.nature: Represent securities held by Co-Investment V, including indirect interests of BCC and Management V. BCC and Management V each disclaims beneficial ownership with respect to these securities, except to the extent of their pecuniary interest therein. Read SEC document |
| March 16, 2020 Filed Mar 16, 2020 17:12 UTC | Enliven Therapeutics, Inc. IMRA · Entity 4024 | ConversionSeries Seed Preferred Stock · Derivative | 281,878 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-008488 · doc4.xml · derivative · entry 3 GOLDFISCHER CARL · CIK 0001110780 · Director · 10% owner BAY CITY CAPITAL LLC · CIK 0001288452 · 10% owner Bay City Capital Management V LLC · CIK 0001461543 · 10% owner Bay City Capital Fund V, L.P. · CIK 0001401826 · 10% owner Bay City Capital Fund V Co-Investment Fund, L.P. · CIK 0001409813 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By entities affiliated with Bay City Capital LLC Disclosed balance after: 0 Underlying: Common Stock · 44,749 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: On March 16, 2020, the Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F4 · price: On March 16, 2020, the Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F4 · derivative.exercise_date: On March 16, 2020, the Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F4 · derivative.expiration_date: On March 16, 2020, the Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F1 · ownership.nature: Bay City Capital LLC, a Delaware limited liability company ("BCC"), Bay City Capital Management V LLC, a Delaware limited liability company ("Management V"), Bay City Capital Fund V, L.P., a Delaware limited partnership ("Fund V"), and Bay City Capital Fund V Co-Investment Fund, L.P., a Delaware limited partnership ("Co-Investment V") are deemed to be a "group" for the purposes of Section 13(d) under the Securities Exchange Act of 1934. Management V is the general partner of Fund V and Co-Investment V and has sole voting and dispositive power with respect to the securities held by Fund V and Co-Investment V. BCC, the manager of Management V, is also an advisor to Fund V and Co-Investment V and has sole voting and dispositive power with respect to the securities held by Fund V and Co-Investment V. Carl Goldfischer, a Managing Director of BCC, is a member of the Issuer's Board of Directors. F2 · ownership.nature: Represent securities held by Fund V, including indirect interests of BCC and Management V. BCC and Management V each disclaims beneficial ownership with respect to these securities, except to the extent of their pecuniary interest therein. Read SEC document |
| March 16, 2020 Filed Mar 16, 2020 17:12 UTC | Enliven Therapeutics, Inc. IMRA · Entity 4024 | ConversionCommon Stock | 13,148 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-008488 · doc4.xml · nonDerivative · entry 2 GOLDFISCHER CARL · CIK 0001110780 · Director · 10% owner BAY CITY CAPITAL LLC · CIK 0001288452 · 10% owner Bay City Capital Management V LLC · CIK 0001461543 · 10% owner Bay City Capital Fund V, L.P. · CIK 0001401826 · 10% owner Bay City Capital Fund V Co-Investment Fund, L.P. · CIK 0001409813 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By entities affiliated with Bay City Capital LLC Disclosed balance after: 703,380 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: On March 16, 2020, the Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F1 · ownership.nature: Bay City Capital LLC, a Delaware limited liability company ("BCC"), Bay City Capital Management V LLC, a Delaware limited liability company ("Management V"), Bay City Capital Fund V, L.P., a Delaware limited partnership ("Fund V"), and Bay City Capital Fund V Co-Investment Fund, L.P., a Delaware limited partnership ("Co-Investment V") are deemed to be a "group" for the purposes of Section 13(d) under the Securities Exchange Act of 1934. Management V is the general partner of Fund V and Co-Investment V and has sole voting and dispositive power with respect to the securities held by Fund V and Co-Investment V. BCC, the manager of Management V, is also an advisor to Fund V and Co-Investment V and has sole voting and dispositive power with respect to the securities held by Fund V and Co-Investment V. Carl Goldfischer, a Managing Director of BCC, is a member of the Issuer's Board of Directors. F3 · ownership.nature: Represent securities held by Co-Investment V, including indirect interests of BCC and Management V. BCC and Management V each disclaims beneficial ownership with respect to these securities, except to the extent of their pecuniary interest therein. Read SEC document |
| March 16, 2020 Filed Mar 16, 2020 17:12 UTC | Enliven Therapeutics, Inc. IMRA · Entity 4024 | ConversionCommon Stock | 690,232 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-008488 · doc4.xml · nonDerivative · entry 1 GOLDFISCHER CARL · CIK 0001110780 · Director · 10% owner BAY CITY CAPITAL LLC · CIK 0001288452 · 10% owner Bay City Capital Management V LLC · CIK 0001461543 · 10% owner Bay City Capital Fund V, L.P. · CIK 0001401826 · 10% owner Bay City Capital Fund V Co-Investment Fund, L.P. · CIK 0001409813 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By entities affiliated with Bay City Capital LLC Disclosed balance after: 690,232 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: On March 16, 2020, the Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F1 · ownership.nature: Bay City Capital LLC, a Delaware limited liability company ("BCC"), Bay City Capital Management V LLC, a Delaware limited liability company ("Management V"), Bay City Capital Fund V, L.P., a Delaware limited partnership ("Fund V"), and Bay City Capital Fund V Co-Investment Fund, L.P., a Delaware limited partnership ("Co-Investment V") are deemed to be a "group" for the purposes of Section 13(d) under the Securities Exchange Act of 1934. Management V is the general partner of Fund V and Co-Investment V and has sole voting and dispositive power with respect to the securities held by Fund V and Co-Investment V. BCC, the manager of Management V, is also an advisor to Fund V and Co-Investment V and has sole voting and dispositive power with respect to the securities held by Fund V and Co-Investment V. Carl Goldfischer, a Managing Director of BCC, is a member of the Issuer's Board of Directors. F2 · ownership.nature: Represent securities held by Fund V, including indirect interests of BCC and Management V. BCC and Management V each disclaims beneficial ownership with respect to these securities, except to the extent of their pecuniary interest therein. Read SEC document |
| May 31, 2019 Filed Jun 7, 2019 16:28 UTC | Epizyme, Inc. EPZM · Entity 12703 | GrantStock Option (Right to Buy) · Derivative | 17,633 | $0.00 Strike: $13.74 | $0.00 |
DisclosureSEC source: 0000899243-19-016018 · doc4.xml · derivative · entry 1 GOLDFISCHER CARL · CIK 0001110780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,633 Underlying: Common Stock · 17,633 shares Expires 2029-05-30 F1 · derivative.exercise_date: This option will vest in full on May 31, 2020, subject to Reporting Person's continued service as a director. In the event of a change in control of the Issuer, the option will become exercisable in full. Read SEC document |
| February 07, 2019 Filed Feb 8, 2019 20:21 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | Exercise / conversionStock Option (right to buy) · Derivative | 9,340 | $0.00 Strike: $5.50 | $0.00 |
DisclosureSEC source: 0001333277-19-000034 · edgar.xml · derivative · entry 5 GOLDFISCHER CARL · CIK 0001110780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,340 shares Expires 2027-06-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| February 07, 2019 Filed Feb 8, 2019 20:21 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | Exercise / conversionStock Option (right to buy) · Derivative | 2,335 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0001333277-19-000034 · edgar.xml · derivative · entry 4 GOLDFISCHER CARL · CIK 0001110780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,335 shares Expires 2023-12-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| February 07, 2019 Filed Feb 8, 2019 20:21 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | SaleCommon Stock | 11,675 | $9.02 | $105,328.35 |
DisclosureSEC source: 0001333277-19-000034 · edgar.xml · nonDerivative · entry 3 GOLDFISCHER CARL · CIK 0001110780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.00 to $9.09, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 07, 2019 Filed Feb 8, 2019 20:21 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | Exercise / conversionCommon Stock | 9,340 | $5.50 | $51,370.00 |
DisclosureSEC source: 0001333277-19-000034 · edgar.xml · nonDerivative · entry 2 GOLDFISCHER CARL · CIK 0001110780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,675 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 07, 2019 Filed Feb 8, 2019 20:21 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | Exercise / conversionCommon Stock | 2,335 | $5.00 | $11,675.00 |
DisclosureSEC source: 0001333277-19-000034 · edgar.xml · nonDerivative · entry 1 GOLDFISCHER CARL · CIK 0001110780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,335 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 29, 2019 Filed Jan 31, 2019 17:20 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | GrantStock Option (right to buy) · Derivative | 27,705 | $0.00 Strike: $8.43 | $0.00 |
DisclosureSEC source: 0001333277-19-000020 · edgar.xml · derivative · entry 1 GOLDFISCHER CARL · CIK 0001110780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,705 Underlying: Common Stock · 27,705 shares Expires 2029-01-28 F1 · derivative.exercise_date: The option vests as to 1/12 of the underlying shares monthly from January 1, 2019. Read SEC document |
| May 18, 2018 Filed May 31, 2018 16:24 UTC | Epizyme, Inc. EPZM · Entity 12703 | GrantStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001209191-18-034362 · doc4.xml · derivative · entry 1 GOLDFISCHER CARL · CIK 0001110780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2028-05-17 F1 · derivative.exercise_date: This option was granted on May 18, 2018, pursuant to the Company's 2013 Stock Incentive Plan with respect to 12,500 shares of Common Stock and vests in full on May 18, 2019 and, in the event of a change in control of the Company, the vesting will accelerate in full. Read SEC document |
| March 22, 2018 Filed Mar 23, 2018 16:56 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | Exercise / conversionStock Option (right to buy) · Derivative | 5,660 | $0.00 Strike: $5.50 | $0.00 |
DisclosureSEC source: 0001333277-18-000035 · edgar.xml · derivative · entry 6 GOLDFISCHER CARL · CIK 0001110780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,340 Underlying: Common Stock · 5,660 shares Expires 2027-06-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vests as to 1/12 of the underlying shares monthly from June 1, 2017. Read SEC document |
| March 22, 2018 Filed Mar 23, 2018 16:56 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | Exercise / conversionStock Option (right to buy) · Derivative | 2,870 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0001333277-18-000035 · edgar.xml · derivative · entry 5 GOLDFISCHER CARL · CIK 0001110780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,870 shares Expires 2024-01-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| March 22, 2018 Filed Mar 23, 2018 16:56 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | Exercise / conversionStock Option (right to buy) · Derivative | 6,470 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0001333277-18-000035 · edgar.xml · derivative · entry 4 GOLDFISCHER CARL · CIK 0001110780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,470 shares Expires 2023-10-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| March 22, 2018 Filed Mar 23, 2018 16:56 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | SaleCommon Stock | 15,000 | $13.03 | $195,375.00 |
DisclosureSEC source: 0001333277-18-000035 · edgar.xml · nonDerivative · entry 3 GOLDFISCHER CARL · CIK 0001110780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $13.00 to $13.15, inclusive. The reporting person undertakes tp provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 22, 2018 Filed Mar 23, 2018 16:56 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | Exercise / conversionCommon Stock | 5,660 | $5.50 | $31,130.00 |
DisclosureSEC source: 0001333277-18-000035 · edgar.xml · nonDerivative · entry 2 GOLDFISCHER CARL · CIK 0001110780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 22, 2018 Filed Mar 23, 2018 16:56 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | Exercise / conversionCommon Stock | 9,340 | $5.00 | $46,700.00 |
DisclosureSEC source: 0001333277-18-000035 · edgar.xml · nonDerivative · entry 1 GOLDFISCHER CARL · CIK 0001110780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,340 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 24, 2018 Filed Jan 26, 2018 17:00 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | GrantStock Option (right to buy) · Derivative | 16,000 | $0.00 Strike: $11.69 | $0.00 |
DisclosureSEC source: 0001333277-18-000020 · edgar.xml · derivative · entry 1 GOLDFISCHER CARL · CIK 0001110780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2028-01-23 F1 · derivative.exercise_date: The option vests as to 1/12 of the underlying shares monthly beginning January 1, 2018. Read SEC document |
| November 02, 2017 Filed Nov 6, 2017 20:45 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | Exercise / conversionStock Option (right to buy) · Derivative | 9,000 | $0.00 Strike: $2.97 | $0.00 |
DisclosureSEC source: 0001209191-17-059524 · doc4.xml · derivative · entry 5 GOLDFISCHER CARL · CIK 0001110780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,000 shares Expires 2025-06-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| November 02, 2017 Filed Nov 6, 2017 20:45 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | Exercise / conversionStock Option (right to buy) · Derivative | 9,000 | $0.00 Strike: $1.72 | $0.00 |
DisclosureSEC source: 0001209191-17-059524 · doc4.xml · derivative · entry 4 GOLDFISCHER CARL · CIK 0001110780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,000 shares Expires 2026-06-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.